Follow
Peter Atadja
Peter Atadja
Exective Director of Drug Discovery, Novartis Insititutes for Biomedical Research
Verified email at novartis.com
Title
Cited by
Cited by
Year
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
H Gao, JM Korn, S Ferretti, JE Monahan, Y Wang, M Singh, C Zhang, ...
Nature medicine 21 (11), 1318-1325, 2015
10612015
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family
L Gao, MA Cueto, F Asselbergs, P Atadja
Journal of Biological Chemistry 277 (28), 25748-25755, 2002
9282002
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase …
P Bali, M Pranpat, J Bradner, M Balasis, W Fiskus, F Guo, K Rocha, ...
Journal of Biological Chemistry 280 (29), 26729-26734, 2005
9142005
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
W Qi, HM Chan, L Teng, L Li, S Chuai, R Zhang, J Zeng, M Li, H Fan, ...
Proceedings of the National Academy of Sciences 109 (52), 21360-21365, 2012
6052012
Epigenetics in cancer: Targeting chromatin modificationsThe Role of Altered Epigenetics in Cancer Development
L Ellis, PW Atadja, RW Johnstone
Molecular cancer therapeutics 8 (6), 1409-1420, 2009
5742009
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
A Villagra, F Cheng, HW Wang, I Suarez, M Glozak, M Maurin, D Nguyen, ...
Nature immunology 10 (1), 92-100, 2009
4592009
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges
P Atadja
Cancer letters 280 (2), 233-241, 2009
4482009
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George, P Bali, S Annavarapu, A Scuto, W Fiskus, F Guo, C Sigua, ...
Blood 105 (4), 1768-1776, 2005
4242005
Increased activity of p53 in senescing fibroblasts.
P Atadja, H Wong, I Garkavtsev, C Veillette, K Riabowol
Proceedings of the National Academy of Sciences 92 (18), 8348-8352, 1995
4221995
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
W Fiskus, Y Wang, A Sreekumar, KM Buckley, H Shi, A Jillella, C Ustun, ...
Blood, The Journal of the American Society of Hematology 114 (13), 2733-2743, 2009
3962009
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, ...
Blood 108 (10), 3441-3449, 2006
3862006
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or-refractory …
R Nimmanapalli, L Fuino, P Bali, M Gasparetto, M Glozak, J Tao, ...
Cancer research 63 (16), 5126-5135, 2003
3532003
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
DZ Qian, SK Kachhap, SJ Collis, HMW Verheul, MA Carducci, P Atadja, ...
Cancer research 66 (17), 8814-8821, 2006
3482006
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
L Ellis, Y Pan, GK Smyth, DJ George, C McCormack, R Williams-Truax, ...
Clinical Cancer Research 14 (14), 4500-4510, 2008
3332008
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B
L Fuino, P Bali, S Wittmann, S Donapaty, F Guo, H Yamaguchi, HG Wang, ...
Molecular cancer therapeutics 2 (10), 971-984, 2003
3322003
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian, Y Kato, S Shabbeer, Y Wei, HMW Verheul, B Salumbides, ...
Clinical Cancer Research 12 (2), 634-642, 2006
3162006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
P Maiso, X Carvajal-Vergara, EM Ocio, R López-Pérez, G Mateo, ...
Cancer research 66 (11), 5781-5789, 2006
2872006
Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia
F Cao, EC Townsend, H Karatas, J Xu, L Li, S Lee, L Liu, Y Chen, ...
Molecular cell 53 (2), 247-261, 2014
2842014
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor …
DZ Qian, X Wang, SK Kachhap, Y Kato, Y Wei, L Zhang, P Atadja, R Pili
Cancer research 64 (18), 6626-6634, 2004
2692004
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity …
F Guo, C Sigua, J Tao, P Bali, P George, Y Li, S Wittmann, L Moscinski, ...
Cancer research 64 (7), 2580-2589, 2004
2612004
The system can't perform the operation now. Try again later.
Articles 1–20